Mayzent (BioDeep_00000176415)
human metabolite blood metabolite
代谢物信息卡片
化学式: C29H35F3N2O3 (516.2599636)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1=C(CN2CC(C2)C(O)=O)C=CC(=C1)C(C)=NOCC1=CC(=C(C=C1)C1CCCCC1)C(F)(F)F
InChI: InChI=1S/C29H35F3N2O3/c1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32/h9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36)
描述信息
同义名列表
6 个代谢物同义名
1-({4-[1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid; 1-({4-[1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylate; 1-(4-(1-((e)-4-Cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl)-2-ethylbenzyl)-azetidine-3-carboxylic acid; Siponimod; BAF-312; Mayzent
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Thomas Hach, Kasra Shakeri-Nejad, Marc Bigaud, Frank Dahlke, Massimiliano de Micco, Olivier Petricoul, Gordon Graham, Daniela Piani-Meier, Renato Turrini, Volker Brinkmann, Ferdinando Nicoletti. Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
2022 Nov; ?(?):. doi:
10.1089/jir.2022.0078. [PMID: 36454249] - Shian Liu, Navid Paknejad, Lan Zhu, Yasuyuki Kihara, Manisha Ray, Jerold Chun, Wei Liu, Richard K Hite, Xin-Yun Huang. Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
Nature communications.
2022 02; 13(1):731. doi:
10.1038/s41467-022-28417-2. [PMID: 35136060] - Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek. Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.
Multiple sclerosis and related disorders.
2022 Jan; 57(?):103435. doi:
10.1016/j.msard.2021.103435. [PMID: 34920248] - Yuan Yuan, Guowen Jia, Chao Wu, Wei Wang, Lin Cheng, Qian Li, Ziyan Li, Kaidong Luo, Shengyong Yang, Wei Yan, Zhaoming Su, Zhenhua Shao. Structures of signaling complexes of lipid receptors S1PR1 and S1PR5 reveal mechanisms of activation and drug recognition.
Cell research.
2021 12; 31(12):1263-1274. doi:
10.1038/s41422-021-00566-x. [PMID: 34526663] - Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, Bruce Anthony Campbell Cree, Benjamin M Greenberg, Uma Kundu, Thomas Hach, Virginia DeLasHeras, Brian J Ward, Joseph Berger. COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Neurology(R) neuroimmunology & neuroinflammation.
2021 11; 9(1):. doi:
10.1212/nxi.0000000000001092. [PMID: 34848501] - Jerold Chun, Gavin Giovannoni, Samuel F Hunter. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Drugs.
2021 Feb; 81(2):207-231. doi:
10.1007/s40265-020-01431-8. [PMID: 33289881] - D-M Zhang, S-L Chen. Cytokine storms caused by novel coronavirus 2019 and treatment for cardiac injury.
European review for medical and pharmacological sciences.
2020 12; 24(23):12527-12535. doi:
10.26355/eurrev_202012_24050. [PMID: 33336773] - Malgorzata Kloc, Rafik M Ghobrial. The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Multiple sclerosis and related disorders.
2020 Oct; 45(?):102437. doi:
10.1016/j.msard.2020.102437. [PMID: 32763844] - Anne Gardin, Kasra Shakeri-Nejad, Andrea Feller, Felix Huth, Srikanth Neelakantham, Swati Dumitras. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
European journal of clinical pharmacology.
2019 Nov; 75(11):1565-1574. doi:
10.1007/s00228-019-02729-7. [PMID: 31392364] - Anne Gardin, Mike Ufer, Eric Legangneux, Gianluca Rossato, Yi Jin, Zhenzhong Su, Parasar Pal, Wenkui Li, Kasra Shakeri-Nejad. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
Clinical pharmacokinetics.
2019 03; 58(3):349-361. doi:
10.1007/s40262-018-0700-3. [PMID: 30088221] - Anne Gardin, Cathy Gray, Srikanth Neelakantham, Felix Huth, Antonia M Davidson, Swati Dumitras, Eric Legangneux, Kasra Shakeri-Nejad. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
European journal of clinical pharmacology.
2018 Dec; 74(12):1593-1604. doi:
10.1007/s00228-018-2533-2. [PMID: 30105453] - Ulrike Glaenzel, Yi Jin, Robert Nufer, Wenkui Li, Kirsten Schroer, Sylvie Adam-Stitah, Sjoerd Peter van Marle, Eric Legangneux, Hubert Borell, Alexander D James, Axel Meissner, Gian Camenisch, Anne Gardin. Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Drug metabolism and disposition: the biological fate of chemicals.
2018 07; 46(7):1001-1013. doi:
10.1124/dmd.117.079574. [PMID: 29735753] - Andreas Pelz, Hanne Schaffert, Radharani Diallo, Falk Hiepe, Andreas Meisel, Siegfried Kohler. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
European journal of immunology.
2018 03; 48(3):498-508. doi:
10.1002/eji.201747187. [PMID: 29205338] - Anne Gardin, Angela Dodman, Sampath Kalluri, Srikanth Neelakantham, Xuemei Tan, Eric Legangneux, Kasra Shakeri-Nejad. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
International journal of clinical pharmacology and therapeutics.
2017 Jan; 55(1):54-65. doi:
10.5414/cp202608. [PMID: 27841151] - Kasra Shakeri-Nejad, Vassilios Aslanis, Uday Kiran Veldandi, Anne Gardin, Andreas Zaehringer, Angela Dodman, Zhenzhong Su, Eric Legangneux. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
International journal of clinical pharmacology and therapeutics.
2017 Jan; 55(1):41-53. doi:
10.5414/cp202588. [PMID: 27443658] - Catherine O'Sullivan, Anna Schubart, Anis K Mir, Kumlesh K Dev. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
Journal of neuroinflammation.
2016 Feb; 13(?):31. doi:
10.1186/s12974-016-0494-x. [PMID: 26856814] - Ryan M Fryer, Akalushi Muthukumarana, Paul C Harrison, Suzanne Nodop Mazurek, Rong Rhonda Chen, Kyle E Harrington, Roger M Dinallo, Joshua C Horan, Lori Patnaude, Louise K Modis, Glenn A Reinhart. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
PloS one.
2012; 7(12):e52985. doi:
10.1371/journal.pone.0052985. [PMID: 23285242]